Abilify Maintena 400 Mg Injection. ABILIFY MAINTENA 1 FL 400 MG+ 1 FL 2 ML Apotheek Thiels Dosage Overview for the Treatment of Schizophrenia and Maintenance Monotherapy of Bipolar I Disorder ABILIFY MAINTENA is only to be administered by intramuscular injection by a healthcare professional For patients naïve to aripiprazole, establish tolerability with oral aripiprazole prior to initiating ABILIFY MAINTENA (2.1) Recommended starting and maintenance dose is 400 mg administered monthly as a single injection
ABILIFY Maintena 400 mg P.+L.z.H.e.DepotInjsusp. 1 St mit dem ERezept kaufen Shop Apotheke from www.shop-apotheke.com
The recommended starting and maintenance dose of ABILIFY MAINTENA is 400 mg monthly (no sooner than 26 days after the previous injection) Abilify Maintena (aripiprazole) is an atypical antipsychotic used to treat schizophrenia and bipolar I disorder
ABILIFY Maintena 400 mg P.+L.z.H.e.DepotInjsusp. 1 St mit dem ERezept kaufen Shop Apotheke
Aripiprazole prolonged release injectable suspension (Abilify Maintena) is a long-acting injectable (LAI) atypical antipsychotic (AAP) indicated for the maintenance treatment of schizophrenia in stabilized adult patients The initial and usual maintenance dose of aripiprazole is 400 mg once a month One injection start: On the day of initiation, administer one injection of 400 mg Abilify Maintena and continue treatment with 10 mg to 20 mg oral aripiprazole per day for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.
Abilify Maintena Er. Patients must discontinue their current oral antipsychotic upon initiation of ABILIFY ASIMTUFII. Oral aripiprazole, 10-30 mg/day, or another oral antipsychotic must be continued for 2-weeks after the initial dose.
DailyMed ABILIFY MAINTENA aripiprazole kit. One injection start: On the day of initiation, administer one injection of 400 mg Abilify Maintena and continue treatment with 10 mg to 20 mg oral aripiprazole per day for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy. It is an extended-release injectable suspension given once a month.